DK3417862T3 - Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmucosal administration af lipofile prodrugs - Google Patents
Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmucosal administration af lipofile prodrugs Download PDFInfo
- Publication number
- DK3417862T3 DK3417862T3 DK18186075.0T DK18186075T DK3417862T3 DK 3417862 T3 DK3417862 T3 DK 3417862T3 DK 18186075 T DK18186075 T DK 18186075T DK 3417862 T3 DK3417862 T3 DK 3417862T3
- Authority
- DK
- Denmark
- Prior art keywords
- lipofile
- galantamine
- bia
- availability
- products
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261676348P | 2012-07-27 | 2012-07-27 | |
EP12178187 | 2012-07-27 | ||
EP13745810.5A EP2877165B1 (en) | 2012-07-27 | 2013-07-29 | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3417862T3 true DK3417862T3 (da) | 2021-07-12 |
Family
ID=49996636
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18186075.0T DK3417862T3 (da) | 2012-07-27 | 2013-07-29 | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmucosal administration af lipofile prodrugs |
DK13745810.5T DK2877165T3 (da) | 2012-07-27 | 2013-07-29 | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmukosal administration af lipofil prodrug |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13745810.5T DK2877165T3 (da) | 2012-07-27 | 2013-07-29 | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmukosal administration af lipofil prodrug |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150190401A1 (da) |
EP (2) | EP2877165B1 (da) |
JP (2) | JP6272857B2 (da) |
CN (2) | CN104507461A (da) |
AU (1) | AU2013294917B2 (da) |
CA (1) | CA2878135C (da) |
DK (2) | DK3417862T3 (da) |
ES (1) | ES2700473T3 (da) |
HK (1) | HK1206242A1 (da) |
IN (1) | IN2015DN00229A (da) |
PL (2) | PL2877165T3 (da) |
WO (1) | WO2014016430A1 (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
DK3417862T3 (da) * | 2012-07-27 | 2021-07-12 | Neurodyn Life Sciences Inc | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmucosal administration af lipofile prodrugs |
AU2015258814B2 (en) | 2014-05-16 | 2018-04-05 | Synaptec Development Llc | Clearance of amyloid ss |
JP2020033304A (ja) * | 2018-08-30 | 2020-03-05 | 医療法人ふじいやさか | 薬剤又はサプリメント、組成物、及び水素供給器の使用 |
EP4029867A1 (en) * | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
JP2024516911A (ja) * | 2021-05-14 | 2024-04-17 | アルファ コグニション インコーポレイティド | アルファ-1062投与に関する自己保存性組成物及び多回使用型ディスペンサー |
CA3238221A1 (en) * | 2021-11-26 | 2023-06-01 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1248059B (it) * | 1991-06-14 | 1995-01-05 | Miat Spa | Insufflatore multidose per farmaci in polvere |
JP2005507411A (ja) * | 2001-10-31 | 2005-03-17 | ファイザー・プロダクツ・インク | 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。 |
US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
JP2009508903A (ja) * | 2005-09-22 | 2009-03-05 | ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤 |
US20090253654A1 (en) * | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
JP2011504163A (ja) * | 2007-06-08 | 2011-02-03 | ヘルスパートナーズ リサーチ ファウンデーション | 中枢神経系への治療化合物の標的化を高めるための薬学的組成物および方法 |
US20110136231A1 (en) * | 2008-04-11 | 2011-06-09 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
ES2463715T3 (es) * | 2008-04-14 | 2014-05-29 | Neurodyn Life Sciences Inc. | Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano |
US20130317117A1 (en) * | 2010-11-24 | 2013-11-28 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
DK3417862T3 (da) * | 2012-07-27 | 2021-07-12 | Neurodyn Life Sciences Inc | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmucosal administration af lipofile prodrugs |
-
2013
- 2013-07-29 DK DK18186075.0T patent/DK3417862T3/da active
- 2013-07-29 EP EP13745810.5A patent/EP2877165B1/en active Active
- 2013-07-29 PL PL13745810T patent/PL2877165T3/pl unknown
- 2013-07-29 CN CN201380039870.3A patent/CN104507461A/zh active Pending
- 2013-07-29 CN CN201810140325.8A patent/CN108245522A/zh active Pending
- 2013-07-29 WO PCT/EP2013/065880 patent/WO2014016430A1/en active Application Filing
- 2013-07-29 US US14/417,502 patent/US20150190401A1/en not_active Abandoned
- 2013-07-29 JP JP2015523573A patent/JP6272857B2/ja active Active
- 2013-07-29 CA CA2878135A patent/CA2878135C/en active Active
- 2013-07-29 AU AU2013294917A patent/AU2013294917B2/en active Active
- 2013-07-29 PL PL18186075T patent/PL3417862T3/pl unknown
- 2013-07-29 DK DK13745810.5T patent/DK2877165T3/da active
- 2013-07-29 ES ES13745810T patent/ES2700473T3/es active Active
- 2013-07-29 EP EP18186075.0A patent/EP3417862B1/en active Active
-
2015
- 2015-01-09 IN IN229DEN2015 patent/IN2015DN00229A/en unknown
- 2015-07-16 HK HK15106777.9A patent/HK1206242A1/xx unknown
-
2018
- 2018-01-04 JP JP2018000060A patent/JP6574002B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015524423A (ja) | 2015-08-24 |
CA2878135A1 (en) | 2014-01-30 |
PL2877165T3 (pl) | 2019-05-31 |
CN108245522A (zh) | 2018-07-06 |
US20150190401A1 (en) | 2015-07-09 |
ES2700473T3 (es) | 2019-02-18 |
IN2015DN00229A (da) | 2015-06-12 |
EP2877165B1 (en) | 2018-09-05 |
JP6272857B2 (ja) | 2018-01-31 |
CA2878135C (en) | 2019-12-03 |
AU2013294917B2 (en) | 2016-12-15 |
WO2014016430A1 (en) | 2014-01-30 |
EP3417862A1 (en) | 2018-12-26 |
EP3417862B1 (en) | 2021-05-05 |
PL3417862T3 (pl) | 2021-11-22 |
JP6574002B2 (ja) | 2019-09-11 |
DK2877165T3 (da) | 2019-01-02 |
AU2013294917A1 (en) | 2015-01-22 |
HK1206242A1 (en) | 2016-01-08 |
JP2018100272A (ja) | 2018-06-28 |
EP2877165A1 (en) | 2015-06-03 |
CN104507461A (zh) | 2015-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3417862T3 (da) | Forbedret hjerne biotilgængelighed af galantamin ved udvalgte formuleringer og transmucosal administration af lipofile prodrugs | |
HK1212701A1 (zh) | 恩雜魯胺製劑 | |
HK1205697A1 (en) | Prodrugs of hydroxyl-comprising drugs | |
DK2914248T4 (da) | Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme | |
HK1203812A1 (en) | Novel pharmaceutical formulations | |
EP2814487A4 (en) | BENDAMUSTIN FORMULATIONS | |
PL2819982T3 (pl) | Proleki witaminy k | |
HK1210914A1 (en) | Formulations of clomazone | |
CO6940426A2 (es) | Formulaciones farmacéuticas | |
RS65177B1 (sr) | Formulacije bendamustina | |
HK1208178A1 (en) | Racecadotril lipid compositions | |
DK2644189T3 (da) | Stabile bortezomib-formuleringer | |
PL2908835T3 (pl) | Stabilne formulacje | |
BR112014018851A2 (pt) | melhoramento da estabilidade postural administrando droxidopa | |
EP2830614A4 (en) | CYCLIC PRODRUGS FROM DUOCARMYCIN ANALOGUE | |
PT3417862T (pt) | Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos | |
HK1209339A1 (en) | Pharmaceutical formulations | |
BR112014021433A2 (pt) | formulações farmacêuticas | |
EP2884963A4 (en) | STABLE PHARMACEUTICAL FORMULATION OF CABAZITAXEL | |
IL233879A0 (en) | Dry powdered dnase i preparations | |
GB201211403D0 (en) | Pharmaceutical formulations | |
GB201211406D0 (en) | Pharmaceutical formulations | |
TH1401000685B (th) | ผลิตภัณฑ์สวมใส่ชนิดใช้แล้วทิ้ง | |
FR2991883B1 (fr) | Paire de skis asymetriques |